

CV (Curriculum Vitae)



Name: Dr. Abolfazl Khalafi-nezhad

Address: Department of Medical Hematology and Oncology and Bone Marrow Transplantation, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Postal code: 71345-1414

Tel: 07136125610

Mobile: 09173176902

Fax: 07136281473

Email: Akhalafinezhad@gmail.com

Date of Birth: 20/7/1983

Education

- 1) 1997-2001: Ehsan High School, Shiraz, Iran.
- 2) 2001-2008: Doctor of Medicine (M.D.); Shiraz University of Medical Sciences, Shiraz, Iran.
- 3) 2010-2014: Internal medicine residency program; Shiraz University of Medical Sciences, Shiraz, Iran.
- 4) 2015-2018: Hematology and medical oncology fellowship program; Department of Medical Hematology and Oncology and Bone Marrow Transplantation, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Scientific honors

- 1) Ranked first position in national hematology and medical oncology board exam (2018)

Educational experience:

- 1) Assistant Professor, Department of Medical Hematology and Oncology and Bone Marrow Transplantation, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Publications:

- 1) Ghayumi SM, Khalafi-Nezhad A, Jowkar Z. Pulse oximeter oxygen saturation in prediction of arterial oxygen saturation in liver transplant candidates. *Hepat Mon.* 2014;14(4):e15449. Published 2014 Apr 7.
- 2) Shafiei F, Jowkar Z, Fekrazad R, Khalafi-Nezhad A. Micromorphology analysis and bond strength of two adhesives to Er,Cr:YSGG laser-prepared vs. bur-prepared fluorosed enamel. *Microsc Res Tech.* 2014;77(10):779-784.
- 3) Khalafi-Nezhad A, Sagheb MM, Amirmoezi F, Jowkar Z, Dehghanian AR. Comparison of the Effect of Alemtuzumab versus Standard Immune Induction on Early Kidney Allograft Function in Shiraz Transplant Center. *Int J Organ*
- 4) Dehghani M, Dabbaghmanesh MH, Khalafi-Nezhad A, et al. Glomus tumor as a cause of oncogenic osteomalacia. *Clin Cases Miner Bone Metab.* 2017;14(3):359-362.
- 5) Ramzi M, Khalafi-Nezhad A, Iravani Saadi M, Jowkar Z. Association between TLR2 and TLR4 Expression and Response to Induction Therapy in Acute Myeloid Leukemia Patients. *Int J Hematol Oncol Stem Cell Res.*
- 6) Khalafi-Nezhad A, Ebrahimi V, Ahmadpour F, et al. Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer. *Cancer Manag Res.* 2020;12:1447-1456.